Combined application of BNLF2b antibody with VCA-IgA, Rta-IgG, and Zta-IgA in nasopharyngeal carcinoma screening in the Guangxi region
Open Access
- 22 September 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0332606
Abstract
Background: This study aims to assess the diagnostic value of the Epstein-Barr virus (EBV) BNLF2b antibody(P85-Ab), alone or in combination with VCA-IgA, Rta-IgG, and Zta-IgA antibodies, in the context of nasopharyngeal carcinoma (NPC). Methods: The study included 100 NPC patients and 100 healthy controls. Chemiluminescent microparticle immunoassay was utilized to measure P85-Ab levels in the serum samples of both NPC patients and healthy controls. Additionally, the ELISA method was employed to detect serum levels of VCA-IgA, Rta-IgG, and Zta-IgA antibodies. The study analyzed the roles of serum P85-Ab in conjunction with VCA-IgA, Rta-IgG, and Zta-IgA antibodies in the diagnosis of NPC. Results: Serum levels of P85-Ab, VCA-IgA, Rta-IgG, and Zta-IgA antibodies in NPC patients were significantly higher than those in the normal control group (P < 0.05). The area under the receiver operating characteristic curve (AUC) for individual diagnosis of NPC using serum P85-Ab, VCA-IgA, Rta-IgG, and Zta-IgA antibodies were 0.964, 0.916, 0.838, and 0.840, respectively. The AUC for the combined detection of the four markers in diagnosing NPC was 0.996, indicating the optimal diagnostic value of the combined detection. Conclusion: The combined detection of P85-Ab with VCA-IgA, Rta-IgG, and Zta-IgA antibodies demonstrates high diagnostic value for nasopharyngeal carcinoma. Serum P85-Ab may serve as a potential marker for the diagnosis of NPC.Keywords
Funding Information
- Central Government Guidance Fund for Local Science and Technology Development of Guangxi Zhuang Autonomous Region (Guike ZY24212050)
- Guangxi Science and Technology Plan Project (AB25069036)
This publication has 19 references indexed in Scilit:
- Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaJAMA Oncology, 2022
- Utility of Epstein–Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening ProgramsClinical Chemistry, 2022
- A comprehensive risk score for effective risk stratification and screening of nasopharyngeal carcinomaNature Communications, 2021
- EBV-LMP1 promotes radioresistance by inducing protective autophagy through BNIP3 in nasopharyngeal carcinomaCell Death & Disease, 2021
- Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex SerologyJournal of Clinical Microbiology, 2020
- LncRNA SNHG5 promotes nasopharyngeal carcinoma progression by regulating miR-1179/HMGB3 axisBMC Cancer, 2020
- Chemical compound cinobufotalin potently induces FOXO1-stimulated cisplatin sensitivity by antagonizing its binding partner MYH9Signal Transduction and Targeted Therapy, 2019
- Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseasesNature Communications, 2019
- Nasopharyngeal carcinomaThe Lancet, 2019
- Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in TaiwanClinical Cancer Research, 2018